Keywords: Cypress Biosience, BioLineRx, Noveo antipsychotic, Israel Office of Chief Scientist, CYP-1020
Cypress Bioscience in-licenses novel antipsychotic from BioLineRx for potential $365 million
Article | 21 June 2010
San Diego, USA-based Cypress Bioscience has entered into an exclusive North American licensing deal for the development and commercialization of ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- Is failure to adopt business process management putting the pharma industry at risk?
- Ignyta acquires Actagene Oncology and entry into cancer personalized medicine
- New Zealand declines Alexion's funding application for Solaris
- HIV vaccines: small biotech and government-funded organizations will step in where Big Pharma has fallen short, says analyst
- Elan makes "transformational" acquisitions and a divestment
